Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash & Current Investments (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Cash & Current Investments for 15 consecutive years, with $767.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 28.69% year-over-year to $767.4 million, compared with a TTM value of $1.1 billion through Sep 2025, down 9.22%, and an annual FY2025 reading of $767.4 million, down 28.69% over the prior year.
  • Cash & Current Investments was $767.4 million for Q4 2025 at Neurocrine Biosciences, down from $1.1 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $1.2 billion in Q3 2024 and bottomed at $765.9 million in Q3 2021.
  • Average Cash & Current Investments over 4 years is $993.4 million, with a median of $984.7 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments surged 34.15% in 2024, then dropped 28.69% in 2025.
  • Year by year, Cash & Current Investments stood at $765.9 million in 2021, then surged by 35.74% to $1.0 billion in 2023, then increased by 3.51% to $1.1 billion in 2024, then decreased by 28.69% to $767.4 million in 2025.
  • Business Quant data shows Cash & Current Investments for NBIX at $767.4 million in Q4 2025, $1.1 billion in Q3 2025, and $975.6 million in Q2 2025.